Skip to main content
//empty //empty

Akerna Corp., a Denver-based cannabis compliance technology provider, said Wednesday it has entered into an agreement to all of the issued and outstanding shares of Canadian-based Ample Organics Inc. in a cash and stock transaction valued at up to US$45-million.

Toronto-based Ample, which says it serves more than 70 per cent of the Canadian market with its seed-to-sale platform, was recently selected to deliver a national cannabis tracking platform in St. Vincent and The Grenadines in 2020.

Jessica Billingsley, chief executive officer of Akerna, said the acquisition will allow the company to execute “its business strategy of complementing strong organic growth with select acquisitions of highly targeted and synergistic technology companies.”

Story continues below advertisement

Akerna says the deal to acquire Ample is comprised of US$5.7-million cash and US$32.3-million in Akerna stock payable on closing. Additional consideration of US$7.6-million in the form of a stock-based deferred consideration may be paid to Ample shareholders if certain revenue targets are achieved by Ample in calendar 2020. The transaction is expected to close by the end of Q1 2020.

Follow related topics

Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies